Drugs / NAI
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06239220 | Feb 2024 → Jul 2026 overdue | head and neck squamous cell carcinoma | Glenn J. Hanna | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NAI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06239220 ↗ |
| Modality | Protein / enzyme biologic | “NAI (a manufactured protein that stimulates the immune system)” NCT06239220 ↗ |
| Route | Subcutaneous | “via subcutaneous injection (under the skin)” NCT06239220 ↗ |